Create Free Account

By creating account you will get access to hot stocks & personalised emails

Anagenics Ltd

Consumer Defensive AU AN1

0.007AUD
-(-%)

Last update at 2024-05-17T00:00:00Z

Day Range

0.0060.007
LowHigh

52 Week Range

0.0070.03
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -2.19644M -3.64400M -3.75989M -4.81782M -5.88544M
Minority interest - - - - -
Net income -2.66715M -3.64879M -3.38663M -4.90730M -5.90956M
Selling general administrative 4.12M 5.85M 0.06M 5.18M 5.38M
Selling and marketing expenses 1.75M 2.38M 5.89M 2.02M 1.71M
Gross profit 4.05M 5.07M 3.70M 4.85M 5.16M
Reconciled depreciation 0.36M 0.49M 0.45M 0.52M 0.15M
Ebit -1.91746M -2.29851M -3.06815M -4.74657M -5.65040M
Ebitda -1.55764M -1.80383M -2.61563M -4.22791M -5.31555M
Depreciation and amortization 0.36M 0.49M 0.45M 0.52M 0.33M
Non operating income net other - - - - -
Operating income -1.91746M -2.29851M -3.06815M -4.74657M -5.65040M
Other operating expenses 11.03M 13.80M 10.34M 13.81M 14.33M
Interest expense 0.03M 0.07M 0.05M 0.07M 0.24M
Tax provision 0.00787M 0.00478M 0.05M 0.09M 0.02M
Interest income 0.02M 0.03M 0.02M 0.02M 0.08M
Net interest income -0.00958M -0.04152M -0.03148M -0.05150M -0.15817M
Extraordinary items -0.92546M -2.00532M 0.42M -0.55080M -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.45475M 0.00478M 0.05M 0.09M 0.02M
Total revenue 9.11M 9.23M 5.82M 7.38M 7.30M
Total operating expenses 5.97M 9.63M 8.23M 11.28M 12.20M
Cost of revenue 5.06M 4.17M 2.11M 2.53M 2.14M
Total other income expense net -0.27898M 0.46M 0.34M 1.15M 0.97M
Discontinued operations -0.92546M -2.00532M 0.42M -0.55080M -0.55080M
Net income from continuing ops -1.74169M -3.64879M -3.80493M -4.90730M -5.90956M
Net income applicable to common shares -2.66715M -3.64879M -3.38663M -4.90730M -5.90956M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 11.11M 12.92M 13.29M 14.89M 9.79M
Intangible assets 0.00144M 0.02M 1.43M 1.76M 1.76M
Earning assets - - - - -
Other current assets 0.05M 0.12M 0.22M 0.18M 0.25M
Total liab 2.22M 4.64M 2.86M 5.08M 3.93M
Total stockholder equity 8.90M 8.29M 10.43M 9.81M 5.86M
Deferred long term liab - - - - -
Other current liab 0.59M 2.25M 0.64M 2.18M 1.96M
Common stock 65.36M 62.44M 60.28M 56.06M 47.77M
Capital stock 65.36M 62.44M 60.28M 56.06M 47.77M
Retained earnings -56.56854M -53.90139M -50.77746M -47.39082M -42.54091M
Other liab 0.04M 0.12M 0.10M 0.10M 0.00674M
Good will 3.45M 3.45M - - -
Other assets 0.58M - - - -
Cash 2.57M 3.28M 6.73M 6.97M 3.08M
Cash and equivalents 2.57M 3.28M 6.73M 6.97M 3.08M
Total current liabilities 1.71M 3.66M 1.92M 3.48M 2.91M
Current deferred revenue - - - - -
Net debt - -1.52774M -5.29392M -5.00950M -1.79527M
Short term debt 0.00000M 0.90M 0.59M 0.47M 0.27M
Short long term debt - 0.56M 0.34M 0.22M 0.27M
Short long term debt total - 1.76M 1.43M 1.96M 1.29M
Other stockholder equity 0.11M -0.24408M 0.93M 1.14M 0.63M
Property plant equipment 0.77M 0.58M 0.53M 1.50M 0.80M
Total current assets 6.25M 8.77M 11.29M 11.63M 7.23M
Long term investments - - - - -
Net tangible assets 5.38M 4.71M 8.96M 8.05M 4.10M
Short term investments - - - - -
Net receivables 1.04M 0.92M 1.80M 1.87M 2.29M
Long term debt 0.00000M 0.77M 0.60M 1.03M 1.02M
Inventory 2.40M 4.45M 2.55M 2.61M 1.62M
Accounts payable 0.72M 0.50M 0.68M 0.84M 0.69M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -0.24408M 0.93M 1.14M 0.63M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.58M - - - -
Deferred long term asset charges - - - - -
Non current assets total 4.86M 4.15M 2.01M 3.26M 2.56M
Capital lease obligations 0.65M 0.43M 0.49M 0.71M -
Long term debt total 0.46M 0.85M 0.84M 1.34M 1.02M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -1.50875M -0.96820M 0.48M - -0.06568M
Change to liabilities -0.18285M -1.07450M -0.43682M 0.00042M 1.18M
Total cashflows from investing activities -1.50875M -0.96820M 0.48M 0.48M -0.06568M
Net borrowings -0.34279M 0.10M -0.57939M -0.26002M -1.98745M
Total cash from financing activities 2.56M 0.07M 3.50M 7.98M 7.27M
Change to operating activities -0.12585M -0.15575M -1.00844M 0.39M 0.05M
Net income -1.74169M -1.64347M -3.38663M -4.90730M -5.90956M
Change in cash -0.71779M -3.44291M -0.24320M 3.89M 1.47M
Begin period cash flow 3.28M 6.73M 6.97M 3.08M 1.61M
End period cash flow 2.57M 3.28M 6.73M 6.97M 3.08M
Total cash from operating activities -1.78049M -2.54934M -4.11415M -4.01311M -5.93466M
Issuance of capital stock 3.18M - 4.51M 8.85M 10.11M
Depreciation 0.36M 0.38M 0.43M 0.52M 0.15M
Other cashflows from investing activities -0.61978M -0.93226M 0.50M 0.50M 0.50M
Dividends paid 0.27M - 0.05M 0.20M -
Change to inventory 0.04M 0.28M -0.27416M -0.99095M -0.35537M
Change to account receivables -0.05269M 1.32M -0.05973M 0.32M -1.25533M
Sale purchase of stock -0.27143M 0.00000M -0.37899M -0.53583M -0.11479M
Other cashflows from financing activities 0.22M 0.63M -0.26064M -0.03102M -0.26329M
Change to netincome 0.87M 0.26M 0.60M 0.66M 0.46M
Capital expenditures 0.05M 0.04M 0.02M 0.02M 0.07M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.31925M 0.37M 0.93M 1.01M -0.37632M
Stock based compensation 0.02M 0.22M 0.16M 0.46M 0.32M
Other non cash items 0.83M -1.42595M 1.69M 1.74M 0.93M
Free cash flow -1.82586M -2.58529M -0.02247M -4.01311M -6.00034M

Fundamentals

  • Previous Close 0.007
  • Market Cap3.23M
  • Volume635000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.06283M
  • Revenue TTM10.20M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 4.41M
  • Diluted EPS TTM-0.01

Peer Comparison

Sector: Consumer Defensive Industry: Household & Personal Products

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AN1
Anagenics Ltd		 - -% 0.007 - - 0.41 0.58 0.36 -1.7833
MCP
Mcpherson'S Ltd		 - -% 0.49 - 16.08 0.38 0.70 0.45 18.84
PTL
Prestal Holdings Limited		 0.01 5.56% 0.19 - - 0.50 0.82 0.0037 0.36
S66
Star Combo Pharma Ltd		 - -% 0.15 - - 0.64 0.49 0.44 5.47
ZNO
Zoono Group Ltd		 - -% 0.03 - - 10.63 4.48 12.44 -3.6185

Reports Covered

Stock Research & News

View All

Profile

Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names. The company also develops, manufactures, and markets beauty and wellness brands comprising Uspa and evolis. It offers its products through various channels, including clinics, retail stores, wholesale pharmacy and spa/salons, online ecommerce, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

Anagenics Ltd

55 Clarence Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Matthew Dudek Acting Chief Exec. Officer NA
Mr. Dominic Burg Chief Operating Officer NA
Ms. Carolyn Heath Chief Customer Officer & GM of Sales NA
Dr. Graham Robertson Head of R&D NA
Mr. Scott Mitchell Greasley Exec. Director NA
Mr. Lee Tamplin B.A. Company Sec. NA
Mr. Scott Mitchell Greasley CEO, MD & Executive Director NA
Mr. Matthew Dudek Chief Financial & Governance Officer and Company Secretary NA
Dr. Graham Robertson Head of Research & Development NA
Mr. Scott Mitchell Greasley CEO, MD & Executive Director NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.